Results 141 to 150 of about 118,363 (290)

Effect of Social Rank on Gut Microbes and Their Metabolites of Greater Long‐Tailed Hamsters (Tscherskia triton)

Integrative Zoology, EarlyView.
Social rank in greater long‐tailed hamsters (Tscherskia triton) shapes gut microbiota composition and metabolite profiles. Dominant males exhibit a “high‐vigilance, metabolically activated” phenotype, with elevated aggression and specific gut microbiota enriched in energy‐harvesting taxa and fecal queuine.
Da Zhang, Xiaoming Xu, Zhibin Zhang
wiley   +1 more source

Kaempferol Protects Intestinal Health in Chinese Forest Musk Deer Possibly by Regulating Intestinal Microbiota and Inhibiting the NF‐κB/NLRP3 Signaling Pathway

Integrative Zoology, EarlyView.
Kaempferol modulates the tryptophan metabolism pathway by increasing the abundances of Christensenellaceae R7 group, Bacteroides, and Blautia and reducing that of Rikenellaceae RC9 gut group, thereby significantly increasing the levels of ILA and IAA. This process inhibits the activation of NF‐κB/NLRP3 signaling pathway, reduces pro‐inflammatory factor
Xiangyu Liu, Zhanjun Ren, Xiuzhu Sun, Shuhui Wang   +3 more
wiley   +1 more source

Metabolome Diversity Enhances Resistance of Intertidal Clams to Thermal Stress

Integrative Zoology, EarlyView.
Meretrix species are widely distributed intertidal bivalves in China with significant ecological and economic importance, which are sensitive to thermal stress. Our results showed that thermal environments of clam habitats shaped metabolome diversity, which can enhance the resistance of intertidal clams to thermal stress.
Zhi Hu, Xiang‐Tao Wei, Xiaonie Lin, Linxuan Ma, Tianzhe Zhang, Yunwei Dong   +5 more
wiley   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Editorial: Brain serotonergic system

Frontiers in Synaptic Neuroscience, 2023
Mouradian Jr, Gary C., Cooper, Matthew A.   +1 more
openaire   +3 more sources

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

Rare but relevant: Ibogaine and cardiovascular complications—prolonged QT interval and ventricular arrhythmias

Addiction, EarlyView.
Abstract Revived interest in psychedelic‐assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti‐addictive potential. Evidence from observational, open‐label, and limited randomized placebo‐controlled trials indicates that ibogaine and its metabolite noribogaine reduce craving and withdrawal symptoms in ...
Tibor Markus Brunt
wiley   +1 more source

The psychoactive effects of repeated ketamine infusions and their mechanistic role in the treatment of alcohol use disorder: Secondary analysis of a randomised controlled trial

Addiction, EarlyView.
Abstract Background and aims Ketamine assisted psychotherapy is a promising new treatment for alcohol use disorder (AUD). The psychoactive effects of repeated intravenous (IV) ketamine infusions in people with AUD and their mechanistic role in treating AUD are largely unknown.
Cassie Bloy, Ananya Sarma, Bethan Marsh, Lorna Hardy, Meryem Grabski, Merve Mollaahmetoglu, Joshua Shotton, Shamhethan Bhaskaran, Anne Lingford‐Hughes, H. Val Curran, Celia Morgan, Will Lawn   +11 more
wiley   +1 more source

Hippocampal subfield differences in people with and without recreational ketamine use: Insights from multi‐modal neuroimaging

Addiction, EarlyView.
Abstract Background and aims Recreational ketamine use has increased globally and is associated with psychiatric and cognitive concerns. The hippocampus in preclinical models shows damage and working‐memory disruption with repeated dosing. However, whether specific hippocampal subregions may differ in people with chronic ketamine use remains unclear ...
Yi‐Hsuan Liu, Chia‐Chun Hung, Marc N. Potenza, Kun‐Hsien Chou, Pei‐Lin Lee, Chu‐Chung Huang, Chiang‐Shan R. Li, Tony Szu‐Hsien Lee, Ching‐Po Lin   +8 more
wiley   +1 more source

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source